Details for New Drug Application (NDA): 006904
✉ Email this page to a colleague
NDA 006904 describes TERFONYL, which is a drug marketed by Bristol Myers Squibb and is included in one NDA. Additional details are available on the TERFONYL profile page.
The generic ingredient in TERFONYL is trisulfapyrimidines (sulfadiazine;sulfamerazine;sulfamethazine). Additional details are available on the trisulfapyrimidines (sulfadiazine;sulfamerazine;sulfamethazine) profile page.
The generic ingredient in TERFONYL is trisulfapyrimidines (sulfadiazine;sulfamerazine;sulfamethazine). Additional details are available on the trisulfapyrimidines (sulfadiazine;sulfamerazine;sulfamethazine) profile page.
Summary for 006904
| Tradename: | TERFONYL |
| Applicant: | Bristol Myers Squibb |
| Ingredient: | trisulfapyrimidines (sulfadiazine;sulfamerazine;sulfamethazine) |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 167MG;167MG;167MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SUSPENSION;ORAL | Strength | 167MG/5ML;167MG/5ML;167MG/5ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
